rnA-protein interactions play numerous roles in cellular function and disease. here we describe rnA-protein interaction detection (raPid), which uses proximity-dependent protein labeling, based on the BirA* biotin ligase, to rapidly identify the proteins that bind rnA sequences of interest in living cells. raPid displays utility in multiple applications, including in evaluating protein binding to mutant rnA motifs in human genetic disorders, in uncovering potential post-transcriptional networks in breast cancer, and in discovering essential host proteins that interact with Zika virus rnA. to improve the BirA*-labeling component of raPid, moreover, a new mutant BirA* was engineered from Bacillus subtilis, termed BAsu, that enables >1,000-fold faster kinetics and >30-fold increased signal-to-noise ratio over the prior standard Escherichia coli BirA*, thereby enabling direct study of rnA-protein interactions in living cells on a timescale as short as 1 min.
10 nm and has been used to study protein-protein interactions 14, 15 . Biotinylation of target proteins permits stringent washing and reduces background. Phage biology was leveraged to design a tool using BirA* to biotin-tag proteins bound to RNA motifs in living cells followed by streptavidin pulldown and mass spectrometry to identify RNA-proximal proteins via an approach termed RNA-protein interaction detection (RaPID).
development of raPid
RaPID involves two elements-an RNA component and a RaPID protein. The RNA component is comprised of BoxB stem loops flanking any RNA motif of interest (Fig. 1a) . Bacteriophage lambda BoxB stem loops bind the λN peptide at high affinity with a dissociation constant of 200 ± 56 pM 16 . The 22-amino-acid λN peptide fused to the N terminus of the HA-BirA* biotin ligase (λN-HA-BirA*) comprises the protein component. BoxB stem loops recruit the RaPID protein, thereby biotinylating proteins bound to the flanked adjacent RNA motif of interest (Fig. 1a) , permitting streptavidin capture of motif-bound proteins for analysis by western blotting and mass spectrometry (MS).
Validation of raPid with known rnA-protein interactions
EDEN15 is a UG-rich RNA sequence known to bind CELF1 17 . Conventional biotinylated RNA pulldown 18 with EDEN15 yielded ~4-fold enrichment of CELF1 proteins over scrambled controls in HEK293T cells (Supplementary Fig. 1a) . RaPID RNA and protein components were expressed in HEK293T cells in biotincontaining media, then pulldown of biotinylated proteins was performed using streptavidin beads followed by western blotting (RaPID-Western). The EDEN15 sequence demonstrated significantly higher CELF1 pull-down on RaPID-Western compared to two scrambled control sequences (Fig. 1b) . While RaPID cannot be directly compared to conventional biotinylated RNA pulldown methods quantitatively, the latter yields a low enrichment of CELF1 over scrambled control ( Fig. 1b and Supplementary Fig. 1 ). RaPID mass spectrometry (RaPID-MS) was then performed in HEK293T and Huh7 cells, using CRAPome filtering analysis 19 and a significance analysis of interactome (SAINT) threshold score of 0.9 to identify true binding proteins (Supplementary Note 1) . The SAINT algorithm calculates interaction probabilities ranging from 0 to 1. A SAINT score cutoff of 0.9 was used, as in prior studies 19 , to ensure high specificity in identifying RNA-protein associations. SAINT scores were plotted against fold change (FC) obtained through CRAPome analysis 19 . This identified CELF1 as binding partner of the EDEN15 motif in both HEK293T and Huh7 cells ( Fig. 1c and Supplementary Tables 2 and 3) . The identification of CELF1 as binding partner of EDEN15 confirmed RaPID's ability to identify known RNA-protein interactions in living cells.
rnA-protein interaction information
RaPID's capacity to study RNA-protein interactions associated with human disease was next examined. The iron responsive element (IRE) RNA motif in the L-ferritin (FTL) gene transcript is altered by point mutations in Hereditary HyperferritinemiaCataract Syndrome (HHCS) 20 , a disorder characterized by increased serum ferritin levels and early-onset cataracts. IRE motifs are bound by IRE binding proteins, IREB2 and IRP1 (IREB1/ACO1), which regulate the translation/stability of target transcripts in the iron metabolic pathway. RaPID-Western with the wild-type FTL IRE motif showed significant IREB2 enrichment over scrambled controls (Fig. 2a,b) , and RaPID-MS in HEK293T cells identified IREB2 as the top IRE binding partner (Supplementary Table 4 ). Three distinct HHCS FTL IRE point mutations from patients bearing the London, Paris and Verona mutations 20 (Fig. 2a) were then compared to WT for binding to IREB2. Replicate RaPID-Westerns demonstrated that diseaseassociated IRE mutants had lower fold IREB2 binding enrichment compared to wild type IRE ( Fig. 2b and Supplementary Fig. 2) . Moreover, binding loss correlated with increased serum ferritin levels seen in specific HHCS patient mutations 20 (Fig. 2b) , although the magnitude of the differences were not quantitatively proportional. These data are consistent with the notion that the severity of HHCS may relate to the extent of IRE-IREBP protein interaction loss and demonstrate RaPID's sensitivity in assessing the impact of RNA mutations on RNA-protein interactions in living cells.
Increased levels of iron lead to destruction of IREB2 protein and thereby reduce the association of IREB2 with the IRE motif 21 . In contrast, IRP1 binds to iron and has reduced affinity to IRE 21 . We performed RaPID-Western in HEK293T cells with ferric ammonium chloride (FAC) added to media to raise iron levels and evaluated the interaction between IRP1 and the IRE. While DMSO and Deferoxamine (DFO) treatment showed IRE motif interaction with IRP1, there was no interaction detected between IRE and IRP1 upon FAC treatment (Supplementary Fig. 3 ). RaPID can therefore detect changes in RNA-protein interaction in response to exogenous stimuli in living cells.
identification of host proteins associated with ZiKV rnA Zika virus (ZIKV) is associated with fetal microcephaly and Guillain-Barré syndrome in adults 22 . RNA viruses co-opt host proteins at their untranslated regions (UTRs) to aid the viral life cycle 23 . To identify host proteins that bind ZIKV RNA, RaPID-MS was performed using ZIKV UTR sequences from the current epidemic strain (KU527068) (Supplementary Tables 5 and 6 ). Host proteins associated with ZIKV UTR sequences were enriched for cell cycle proteins ( Fig. 2c and Supplementary Table 7) , mirroring Fig. 4a ) 24 . ZIKV is highly neurotropic, thus proteins that bind the ZIKV RNA UTRs were distilled into a subset that display enriched expression in neural tissue ( Supplementary Fig. 4b , Supplementary Table 8 and Supplementary Note 2) 25 . This identified QKI, an RNA-binding protein that is highly expressed in neural progenitor cells (NPCs) 26 , as the ZIKV RNA-binding protein most enriched in neural tissues. To determine if QKI impacts ZIKV replication, QKI was depleted in the U87 glioblastoma cell line ( Supplementary Fig. 4c-e) . QKI loss decreased ZIKV viral RNA levels by 90% (Fig. 2d ) without altering control Coxsackievirus B3 viral RNA levels ( Fig. 2e) , suggesting that QKI is a host protein selectively important for ZIKV replication. Interestingly, Qki mutation in mice leads to abnormal neural development, seizures and white matter loss 27 , which are also observed in congenital ZIKV syndrome. Consistent with this, QKI protein decreases as NPCs differentiate to neurons (Supplementary Fig. 5 ). ZIKV RNA binding to QKI could thus sequester QKI, contributing to a relative QKI deficiency that may impair neural development.
characterization of synthetic rnA motifs
To examine RaPID specificity and to expand the scope of RaPID data generation with a goal to discovering additional RNA-protein interactions, RaPID-MS was performed with three representative conserved RNA motifs (Histone SL-UTRP11, PPP1R3C-UTRP30, IRE-UTRP35) identified by a comparative analysis of 41 vertebrate genomes 28 . Additionally, a synthetic concatamer was generated termed Syn-EIR consisting of the EDEN15, IRE and ROQ CDE motifs, well-characterized RNA motifs that are known to bind CELF1, IREB2 and RC3H1 proteins, respectively. RaPID-MS demonstrated protein-binding selectivity for RNA motifs and Syn-EIR RaPID-MS successfully identified binding of all three proteins to the RNA motif concatamer ( Fig. 3a and Supplementary Fig. 6 ). RaPID thus demonstrates specificity in identifying RNA-proximal proteins and can assess a concatamerized synthetic array of RNA motifs. Fig. 7a ) 30, 31 . RC3H1 and its paralog RC3H2 are known RNA-binding proteins that promote RNA decay 32, 33 . Similar to RC3H1, upregulation of RC3H2 in breast cancer was also correlated with poorer survival (Fig. 3b and Supplementary  Fig. 7b,c) 30, 31 . Upregulation of RC3H1 and RC3H2 in breast cancer is mutually exclusive (Fisher exact test, 0.035) 30, 31 . Tavazoie et al. 29 showed that SM1v1 presence in the 3′ UTR reduces host transcript stability. CLIP-qPCR demonstrated the direct nature of the interaction between SM1v1 RNA and RC3H1 protein, similar to TNF-CDE RNA and RC3H1 positive control (Fig. 3c) , confirming RaPID's ability to identify new RNA-protein interactions. Taken together with breast cancer survival data, these findings raise the possibility that overexpression of RC3H1 may lead to abnormal post-transcriptional control of RNAs bearing SM1v1-like motifs, potentially contributing to an altered disease course.
Additional BirA* proximity-labeling proteins E. coli BirA* requires 16-18 h for optimal labeling 14, 15 . To generate a faster biotin ligase for RaPID, the structure of E. coli BirA* was first compared to other biotin ligases present in the UniProt database. Based on structure and sequence analysis, four motifs were identified: (i) a reactive biotin-5-AMP binding motif (RBAM) (ii) an avidin-like biotin binding motif (ABM), (iii) an adenylation motif (AM) and (iv) a proximal to adenylation motif (PTAM) ( Fig. 4a and Supplementary Fig. 8 ). Mutation of a positively charged arginine residue to glycine in the RBAM motif is critical to reduce affinity of biotin ligase to biotin-5-AMP and thereby permit vicinal labeling. We identified four biotin ligases, in addition to E. coli BirA and Aquifex aeolicus (BioID2), which contain RBAM (Fig. 4a ) 34 . Each of the mutant BirA*s were tagged with HA and transfected at equal amounts. BirA*s from Rhodanabacter spp. and Taneralla spp. expressed at a lower level than other BirA*s, making it difficult to compare their activity to the other four ligases (Supplementary Fig. 9b ). For B. subtilis biotin ligase, the DNA binding domain was identified to be unnecessary for biotinylation 35 . Based on sequence and structural alignment, additional C-terminal mutations were made in the B. subtilis protein (Supplementary Fig. 12d ) to generate the BASU (from Bacillus subtilis) biotin ligase. BASU was then assessed for labeling activity by exposing cells for 1 h in 200 µM biotin media. BASU displayed substantially higher global streptavidin signal relative to other mutant BirA*s ( Fig. 4b and Supplementary Fig. 9b ).
increased labeling kinetics and signal-to-noise ratio of raPid BAsu
To compare BASU to E. coli BirA* and BioID2 in the context of RaPID, the RC3H1 protein-binding TNF-CDE RNA motif 36 was used. First, equal amounts of TNF-CDE RNA motif and BASURaPID protein constructs were transfected in a 6-well plate, with each well biotin labeled from 1 h to 0 min. BASU-RaPID yielded a strong signal in as little as 1 min (Supplementary Fig. 10 ). Next, cells containing the TNF-CDE RNA motif were biotin pulsed for 1 min with either the BioID2 or BASU construct. At 1 min, no RC3H1 pulldown was detected with the BioID2 ( Supplementary  Fig. 11a,b) . BASU, in contrast, displayed ~250-fold enrichment of RC3H1 compared to TNF-CDE RNA motif to scrambled controls ( Supplementary Fig. 11c,d) . The E. coli BirA*-based RaPID protein was tested at its 18-h labeling optimum timepoint, which yielded ~8-fold enrichment of RC3H1 ( Supplementary  Fig. 11e,f) . BASU at 1 min labeling is thus able to achieve >30-fold higher fold enrichment relative to E. coli BirA* at 18 h of labeling (Supplementary Fig. 11g ). To compare specificity, RaPID-MS with BASU was performed using EDEN15 and IRE RNA motifs. As with RaPID-MS performed with E. coli BirA*, BASU RaPID-MS identified CELF1-EDEN15 and IREB2-IRE interactions ( Supplementary Fig. 11h ,i and Supplementary Tables 14  and 15 ). BASU thus improves RaPID labeling speed as well as signal-to-noise ratio with retained specificity. BASU's labeling kinetics and nontoxic reagents suggest it is applicable to short timeframe studies in tissue. Mutant peroxidases perform vicinal labeling (APEX2) with similar speed to BASU, but they require cytotoxic reagents, hydrogen peroxide and biotin-phenol, that preclude their use in tissue and model organisms 37 . E. coli BirA* can study protein-protein interactions in model organisms but has poor labeling kinetics that hinder its use in spatially and temporally resolving protein interactions 15 . To characterize BASU labeling in tissue, 3D organotypic human skin tissue expressing BASU was exposed to biotin for 0 min (baseline) or 30 min. The same experiment was performed with E. coli BirA. While there was no streptavidin signal observed in E. coli BirA, there was substantial increase in streptavidin signal comparing 0-and 30-min timepoint with BASU ( Supplementary Fig. 12) . Thus, BASU enables faster function in living tissue. discussion Here we describe RaPID as a method to identify and study RNA-protein interactions in living cells. RaPID labels RNAassociated proteins in living cells without the need for formaldehyde cross-linking and requires fewer cells than many available methods. Because it can interrogate motifs <50 nucleotides long, RaPID may be of particular utility in studying short RNA sequences inaccessible to other available methods requiring greater sequence length.
RaPID has been used to qualitatively assess impact of diseaseassociated RNA mutations on RNA-protein interactions in living cells. Hence, RaPID could serve as a complement to in vitro methods such as EMSA to study RNA-protein interactions. Moreover, RaPID could help to assay impact of small molecules on RNAprotein interactions. This potentially opens up the opportunity to design and test small molecules against an array of natural and disease variant RNA motifs in living cells. In infectious disease, shows direct interaction between SM1v1 motif and HA-RC3H1 compared to HA-mCherry (P < 0.0001, exact P value = 0.00005891, P values were calculated using unpaired t-test The approach presented here has some limitations in its current form. For example, because biotin-ligase-based proximity proteomics is based on biotinylation of lysine residues of proteins, it has the limitation that not all proteins may be equally detected because of variation in lysines exposed on the surface of proximal proteins. As a modular framework, however, RaPID is not limited to use of biotin ligases; and other vicinal labeling approaches, such as APEX2 37 , may be used. Cells have endogenously biotinylated protein, and each cell type may have a different set of background biotinylated proteins. Hence, using scrambled sequences along with motifs of interest is an important control when performing RaPID-MS and subsequent CRAPome analysis to subtract background proteins and to identify true proximal proteins. With HEK293T cells, we collated a reference list of highly biotinylated background proteins (Supplementary Table 16 ). Moreover, RaPID cannot distinguish between directly interacting proteins or proteins that engage indirectly with RNA, and it cannot be used to study endogenous RNAs at their physiological concentrations. The latter limitation, however, may be addressed in the future by increasingly efficient approaches to homology-directed recombinatorial knock-in technologies, which may permit incorporation of BoxB sites into endogenous RNA sequences expressed from native regulatory elements 38 . methods Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
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RaPID-Western. On day of harvest, cells were washed with cold PBS (1×). Compositions of buffers used are described in Supplementary Table 15 . Volumes mentioned in this section are for sample from individual well of a 6-well plate. Lysis was performed with 200 µL lysis buffer at room temperature. 20 µL of 25% Triton X-100 was added and mixed thoroughly. Then, 220 µL of cold 50 mM Tris pH 7.4 was added, following which samples were sonicated for 10 s. Lysate was spun down at 4 °C for 10 min. Protein concentration in each sample was quantified using spectrophotometer with Pierce Protein Quantitation Assay (ThermoFisher). Protein concentration across samples was normalized, and 40 µL of the sample was taken and labeled as Lysate. Pull down of biotinylated proteins was performed with MyOne C1 Streptavidin Beads (Thermofisher), and sample was rotated with beads for 2 h at room temperature. Three washes were performed as described previously 14 . Beads were then boiled in Elution Buffer for 45 min at 98 °C and labeled as Pulldown. Both Pulldown & Lysate samples were loaded and run out on 4-12% Bis-Tris gel (Thermofisher) and electrotransferred to nitrocellulose membrane. Membrane was blocked in blocking buffer (LI-COR Biosciences 927-40000) for 1 h and subsequently incubated with primary antibodies overnight. Primary Antibodies used: anti-HA (Cell Signaling) anti-CELF1 (Santa Cruz Biotechnology, sc-20003), anti-IREB2 (Santa Cruz Biotechnology, sc-33682). Membranes were washed with PBS-T and incubated with secondary goat anti-mouse and goat anti-rabbit antibodies (LI-COR Biosciences 925-32210, 925-32211) at a dilution of 1:4,000 for 1 h at room temperature. The membrane was then washed with PBS-T and visualized using the Odyssey CLx Infrared Imaging System (LI-COR Biosciences). Quantification was performed using the Licor ImageStudioLite software (LI-COR Biosciences).
RaPID-MS.
For sample preparation for LC-MS/MS, streptavidin biotin magnetic particles were washed with 500 µL 50 mM ammonium bicarbonate three times. Beads were resuspended in 200 µL 50 mM ammonium bicarbonate with the addition of DTT to a final concentration of 5 mM, incubated on a heat block at 50 °C for 5 min followed by head-over-head rocking for 30 min at room temperature. Alkylation was performed by the addition of propionamide to a final concentration of 10 mM and head-over-head shaking for 30 min at room temperature. 250 ng of trypsin/LysC (Promega) was added to each sample and digested overnight at room temperature in the head-over-head shaker followed by the addition of formic acid to 1%. Peptides were removed and washed with 50 µL 0.1% formic acid water. The acidified peptide pools were C18 STAGE tip 40 purified (NEST group) using microspin columns and dried in a speed vac 40 . For LC-MS/MS, peptide pools were reconstituted and injected onto a C18 reversed-phase analytical column 10 cm in length (New Objective). The UPLC was a Waters NanoAcquity, operated at 600 nL/min using a linear gradient from 4% mobile phase B to 35% B. Mobile phase A consisted of 0.1% formic acid, water; mobile phase B was 0.1% formic acid, water. The mass spectrometer was an Orbitrap Elite set to acquire data in a data-dependent fashion selecting and fragmenting the 15 most intense precursor ions in the ion trap where the exclusion window was set at 60 s, and multiple charge states of the same ion were allowed.
LC-MS/MS data analysis.
MS/MS data were analyzed using both Preview and Byonic v1.4 (ProteinMetrics). All data were first analyzed in Preview to provide recalibration criteria and then reformatted to .MGF before full analysis with Byonic. Analyses used Uniprot canonical .fasta files for Human, concatenated with common contaminant proteins. Data were searched at 10 p.p.m. mass tolerances for precursors, with 0.4 Da fragment mass tolerances assuming up to two missed cleavages and allowing for N-ragged tryptic digestion. These data were validated at a 1% false discovery rate using typical reverse-decoy techniques. The resulting identified peptide spectral matches and assigned proteins were then exported for further analysis using custom tools developed in MatLab (MathWorks) to provide visualization and statistical characterization. SAINT scores were generated using the online CRAPome tool with spectral counts from experimental samples and controls (Supplementary Note 1) 19 .
hiPSC-derived NPCs and neurons. Episomally derived human induced pluripotent stem cells were differentiated using a combination of SMAD inhibition and retinoid signaling 41, 42 RNA motif qPCR quantification. HEK293T cells were transfected in 12-well plate (100,000 cells per well) with 0.5 µg of RNA motif construct. All RNA motif constructs had eGFP at the ORF and the motif at 3′ UTR (Supplementary Fig. 1a ). Cells were collected 48 h post-transfection and RNA prepared using RNeasy Plus mini kit (Qiagen) according to the manufacturer's instructions. 1 µg of total RNA was reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad). qRT-PCR was performed using the Maxima SYBR Green qPCR master mix (2× , Fermentas). Samples were run in triplicate, and samples were normalized to 18S expression. The primers used for the real time quantitative PCR are the following: GFP Forward 5′-GAAGCAGCACGACTTCTTCAA-3′; GFP Reverse: 5′-AAGTCGATGCCCTTCAGCTC-3′ ; 18S Forward 5′-GCAATTATTCCCCATGAACG-3′ ; 18S Reverse 5′-GGCCTCACTAAACCATCCAA-3′.
(IRB-12568 "Gene Expression Analysis of Human Skin Disease"). Lentiviral infection of BASU or E. coli BirA was performed on keratinocytes. BASU or E. coli BirA stably expressing keratinocytes were then seeded on devitalized human dermis along with fibroblasts and grown as described previously 45 .Once 3D organotypic human skin tissue had stratified, 200 µM biotin containing keratinocyte media was added for 30 min to obtain the 30 min timepoint. For 0 min timepoint, no change in media was performed. 3D organotypic human skin tissue was embedded with OTC (Sakura, Torrance, California), and frozen sections were obtained using standard techniques. Antibodies: Streptavidin, Alexa Fluor 488 conjugate (Thermofisher S11223 at 1:100 dilution 1:100 dilution). Immunofluorescence images were taken using Zeiss Axiovert inverted microscope. No data was excluded
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